Literature DB >> 26771055

Medication Safety During Pregnancy: Improving Evidence-Based Practice.

Susan M Sinclair, Richard K Miller, Christina Chambers, Elizabeth M Cooper.   

Abstract

Nearly 90% of women in the United States have taken medications during pregnancy. Medication exposures during pregnancy can result in adverse pregnancy and neonatal outcomes including birth defects, fetal loss, intrauterine growth restriction, prematurity, and longer-term neurodevelopmental outcomes. Advising pregnant women about the safety of medication use during pregnancy is complicated by a lack of data necessary to engage the woman in an informed discussion. Routinely, health care providers turn to the package insert, yet this information can be incomplete and can be based entirely on animal studies. Often, adequate safety data are not available. In a busy clinical setting, health care providers need to be able to quickly locate the most up-to-date information in order to counsel pregnant women concerned about medication exposure. Deciding where to locate the best available information is difficult, particularly when the needed information does not exist. Pregnancy registries are initiated to obtain more data about the safety of specific medication exposures during pregnancy; however, these studies are slow to produce meaningful information, and when they do, the information may not be readily available in a published form. Health care providers have valuable data in their everyday practice that can expand the knowledge base about medication safety during pregnancy. This review aims to discuss the limitations of the package insert regarding medication safety during pregnancy, highlight additional resources available to health care providers to inform practice, and communicate the importance of pregnancy registries for expanding knowledge about medication safety during pregnancy.
© 2016 by the American College of Nurse-Midwives.

Entities:  

Keywords:  drug effects; evidence-based health care; fetus; patient safety; pregnancy; prescription drugs; teratogenesis

Mesh:

Year:  2016        PMID: 26771055     DOI: 10.1111/jmwh.12358

Source DB:  PubMed          Journal:  J Midwifery Womens Health        ISSN: 1526-9523            Impact factor:   2.388


  6 in total

1.  Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.

Authors:  Agnes Kant; Loes de Vries; Leàn Rolfes
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

2.  Assessing SSRIs' effects on fetal cardiomyocytes utilizing placenta-fetus model.

Authors:  Navein Arumugasaamy; Amelia Hurley-Novatny; Josephine Lembong; Peter C W Kim; John P Fisher
Journal:  Acta Biomater       Date:  2019-09-16       Impact factor: 8.947

3.  Model Placental Barrier Phenotypic Response to Fluoxetine and Sertraline: A Comparative Study.

Authors:  Navein Arumugasaamy; Alana Gudelsky; Amelia Hurley-Novatny; Peter C W Kim; John P Fisher
Journal:  Adv Healthc Mater       Date:  2019-08-13       Impact factor: 9.933

4.  An Ethics Framework for Big Data in Health and Research.

Authors:  Vicki Xafis; G Owen Schaefer; Markus K Labude; Iain Brassington; Angela Ballantyne; Hannah Yeefen Lim; Wendy Lipworth; Tamra Lysaght; Cameron Stewart; Shirley Sun; Graeme T Laurie; E Shyong Tai
Journal:  Asian Bioeth Rev       Date:  2019-10-01

5.  Association between paracetamol use during pregnancy and perinatal outcomes: Prospective NISAMI cohort.

Authors:  Caroline Tianeze de Castro; Marcos Pereira; Djanilson Barbosa Dos Santos
Journal:  PLoS One       Date:  2022-04-18       Impact factor: 3.752

6.  Adverse drug reactions in high-risk pregnant women: A prospective study.

Authors:  Alfredo Dias de Oliveira-Filho; Antonio Emanuel Soares Vieira; Roberta Cruz da Silva; Sabrina Joany Felizardo Neves; Thiago Antonio Barros Gama; Ryane Vieira Lima; Wlisses Ramon Oliveira; Júlia Maria de Gonçalves Dias
Journal:  Saudi Pharm J       Date:  2017-02-02       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.